Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 3 13Phase 1/2 11Phase 1 11Phase 2/3 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 49Tumor-Agnostic 3Lymphoid 2Thoracic 1NET 1Endocrine 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 26Rituximab 17Etoposide 16Methotrexate 15Dexamethasone 15Cytarabine 15Vincristine 14Prednisone 11Doxorubicin 11Radiotherapy 10blinatumomab 8fludarabine 7Mercaptopurine 7Filgrastim 7Daunorubicin 7Asparaginase 7pegaspargase 6Granulocyte Colony-Stimulating Factor 6Methylprednisolone 5Drug Therapy 5Dasatinib 5venetoclax 4prednylidene 4etoposide phosphate 4deltacortene 4Trimethoprim, Sulfamethoxazole Drug Combination 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Busulfan 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Oxaliplatin × Lymphoid × Clear all
NCT05139017 2026-06-04

waveLINE-003

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Celgene

Phase 2/3 Completed
111 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡